

## P53 clone DO7

### Instructions For Use

**Specification:**

Anti-p53 Tumor Suppressor Protein antibody recognizes a 53 kDa phosphoprotein, identified as p53 suppressor gene product. It reacts with the mutant as well as wild form of p53. Positive nuclear staining with this antibody has been shown to be a negative prognostic factor in Breast carcinoma, Lung carcinoma, colorectal, and Urothelial carcinoma. p53 positivity has also been used to differentiate Uterine serous carcinoma from endometrioid carcinoma as well as to detect Intratubular germ cell neoplasia.

**Availability:**

Catalog No.	Contents	Volume
ILM27011-C1	P53	0,1 ml concentrate
ILM27011-C05	P53	0,5 ml concentrate
ILM27011-C01	P53	1,0 ml concentrate

**Intended use:** For Research Use Only

**Reactivity:** Human, Monkey and Cow

**Clone:** DO7

**Species of origin:** Mouse

**Isotype:** IgG<sub>2b</sub>/κ

**Control Tissue:** Breast carcinoma, colon carcinoma

**Staining:** Nuclear

**Immunogen:** Recombinant human wild type p53 protein expressed in *E. coli*.

**Presentation:** Bioreactor Concentrate with 0.05% Azide

**Application and suggested dilutions:**


Pretreatment: Heat induced epitope retrieval in 10 mM citrate buffer, pH6.0, for 20 minutes is required for IHC staining on formalin-fixed, paraffin embedded tissue sections.

- Immunohistochemical staining of cryostat tissue sections (dilution 1:50-1:100)
- Immunohistochemical staining of formalin-fixed, paraffin embedded tissue section (dilution 1:50-1:100)
- Western blotting

The optimal dilution for a specific application should be determined by the investigator.

**Note:** Dilution of the antibody in 10% normal goat serum followed by a goat anti-mouse secondary antibody-based detection is recommended.

**Storage & Stability:** Store at 2-8 °C. Do not use after expiration date printed on the vial.



**References:**

- 1) Moore BE et al. Applied Immunohistochemistry and Molecular Morphology 9(3): 203 –206, 2001
- 2) Mauri FA et al. Int J Oncol 1999 Dec;15(6):1137-47
- 3) Cafo O et al. Clin Cancer Res 1996 Sep;2(9):1591-9
- 4) Bebenek M et al. Anticancer Res 1998 Jan-Feb;18(1B):619-23
- 5) Midulla C et al. Anticancer Res 1999 Sep-Oct;19(5B):4033-7
- 6) Dabbs DJ. Diagnostic Immunohistochemistry 2002; Churchill Livingstone
- 7) Zen ZS et al. J Clin. Oncol. 12, 2043-50
- 8) Quinlan DC et al. Cancer Res. 53, 4828-31